The 3rd Microbiome R&D and Business Collaboration Congress: Asia, which will be held on March 1 – 2, 2017 in Hong Kong and co-located with our 2nd Probiotics Congress. Last year’s successful event attracted over 200 attendees.
Recognised around the world, as the leading conferences for bringing together Pharma, Biotech, Academic Institutions and investors who are partnering together to develop and progress ground-breaking microbiome research into commercially viable products. The 2017 congress is not one to miss.
Developments in the field of metagenomics have allowed researchers to explore the diverse microbiota in the human body. Research has shown that the microbiome is linked to natural immunity, metabolism, behavioural traits, and broadly speaking, plays an instrumental role in health and disease. With large-scale collaborative projects underway and sequencing data placed in the public domain, there is a rich source of information for researchers and companies looking for opportunities in this exciting field. Increasingly, there are indications that the human microbiome is key to curative and preventative medicine so efforts are being focused on expanding investment opportunities, performing more clinical trials and spurring innovative research in this area. Coupled with an increasing focus on healthy living and a therapeutics market that is expected to grow to $1.2 trillion by 2016, microbiome research is set to make waves in the science and medical world through its application in preventative treatments, cures, therapies and supplements.
Attracting experts working in all areas of microbiome research, product development and business, the congress will explore the interface between the microbiome and our evolving cultures and technologies. During the two-day conference, there will be networking breaks to promote interaction with your peers, expert led case study presentations, a dynamic exhibition room filled with technology providers showcasing their technologies and solutions, and panel discussions exploring key issues in the field. Together, we can further develop microbiome research across the Asia-Pacific region, and begin to look towards forging collaborations and commercialising the research.
Recognised around the world, as the leading conferences for bringing together Pharma, Biotech, Academic Institutions and investors who are partnering together to develop and progress ground-breaking microbiome research into commercially viable products. The 2017 congress is not one to miss.
Developments in the field of metagenomics have allowed researchers to explore the diverse microbiota in the human body. Research has shown that the microbiome is linked to natural immunity, metabolism, behavioural traits, and broadly speaking, plays an instrumental role in health and disease. With large-scale collaborative projects underway and sequencing data placed in the public domain, there is a rich source of information for researchers and companies looking for opportunities in this exciting field. Increasingly, there are indications that the human microbiome is key to curative and preventative medicine so efforts are being focused on expanding investment opportunities, performing more clinical trials and spurring innovative research in this area. Coupled with an increasing focus on healthy living and a therapeutics market that is expected to grow to $1.2 trillion by 2016, microbiome research is set to make waves in the science and medical world through its application in preventative treatments, cures, therapies and supplements.
Attracting experts working in all areas of microbiome research, product development and business, the congress will explore the interface between the microbiome and our evolving cultures and technologies. During the two-day conference, there will be networking breaks to promote interaction with your peers, expert led case study presentations, a dynamic exhibition room filled with technology providers showcasing their technologies and solutions, and panel discussions exploring key issues in the field. Together, we can further develop microbiome research across the Asia-Pacific region, and begin to look towards forging collaborations and commercialising the research.
